Immunologic challenges in small bowel transplantation

American Journal of Transplantation

Volumn 12, Issue SUPPL 4, 2012, Pages

  Berger, M ^a   Zeevi, A ^b   Farmer, D G ^c   Abu Elmagd, K M ^d  

^a CSL Behring LLC   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

HLA antibody; Immunosuppression; Intestine; Rejection; Small bowel transplantation

Indexed keywords

ALEMTUZUMAB; BORTEZOMIB; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1S INHIBITOR; CORTICOSTEROID; DONOR SPECIFIC ANTIBODY; ECULIZUMAB; HLA ANTIBODY; HUMAN IMMUNOGLOBULIN; LIGAND; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; ANTIBODY; HLA ANTIGEN;

ACUTE GRAFT REJECTION; ALLOGRAFT; ANTIBODY PRODUCTION; ANTIBODY TITER; CELL MIGRATION; CHRONIC GRAFT REJECTION; COMPLEMENT ACTIVATION; COMPLEMENT FIXATION; CONFERENCE PAPER; DIARRHEA; DRUG BINDING; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HLA SYSTEM; HUMAN; HYPERACUTE GRAFT REJECTION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INNATE IMMUNITY; INTESTINE ISCHEMIA; INTESTINE TRANSPLANTATION; KIDNEY GRAFT REJECTION; LIVER GRAFT; LONG TERM CARE; MONITORING; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REPERFUSION INJURY; VASCULAR CLAMP; BLOOD; DONOR; IMMUNOLOGY; METHODOLOGY; ORGAN TRANSPLANTATION; PHYSIOLOGY; SMALL INTESTINE; TRANSPLANTATION;

ANTIBODIES; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNITY, INNATE; IMMUNOSUPPRESSION; INTESTINE, SMALL; ORGAN TRANSPLANTATION; TISSUE DONORS;

EID: 84886577203     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04332.x     Document Type: Conference Paper

References (41)

1. Fishbein TM. Intestinal transplantation. N Engl J Med 2009;361:998-1008.
2. Farmer DG, Venick RS, Colangelo J, et al. Pretransplant predictors of survival after intestinal transplantation: Analysis of a single center experience of more than 100 transplants. Transplantation 2010;90:1574-1580
3. Abu-Elmagd KM, Costa G, Bond GJ, et al. Five hundred intestinal and multivisceral transplantations at a single center: Major advances with new challenges. Ann Surg 2009;250:567-581.
4. Mazariegos GV, Steffick DE, Horslen S, Farmer D, Fryer J, Grant D, Langnas A, Magee JC Intestine Transplantation in the United States, 1999-2008. Am J Transplant 2010;10 Part2:1020-1034.
5. Bland PW, Bailey M. Immunology of the small intestine. Transplant Proc 1998;30:2560-2561 (Pubitemid 28459740)
6. Fishbein T, Novitsky G, Mishra L, et al. NOD2-expressing bone marrow derived cells appear to regulate epithelial innate immunity of the transplanted human small intestine. Gut 2008;57:323-330 (Pubitemid 351288097)
7. Ningappa M, Higgs BW, Weeks DE, et al. NOD2 gene polymorphism rs2066844 associates with need for combined liverntestine transplantation in children with short-gut syndrome. Am J Gastroenterol 2011, Jan 106:157-165
8. Alegre M-L, Chen L, Wang T, Ahmed E, Wang C-R, Chong A. Antagonistic effects of toll-like receptor signaling and bacterial infections on transplantation tolerance. Transplantation 2009;87 Suppl 9:S77-S79.
9. Chen L, Wang T, Zhou P, et al. TLR engagement prevents transplantation tolerance. Am J Transplant 2006;6:2282-2291 (Pubitemid 44359413)
10. Watson MJ, Ke B, Shen X-D, Gao F, Busuttl RW, Kupiec-Weglinski JW, Farmer DG. Intestinal ischemia/reperfusion injury triggers activation of toll-like receptor 4 and adaptive chemokine programs Transplant Proc 2008;40:3339-3341
11. Kumar AR, Li X, LeBlanc JF, Farmer DG, Elashoff D; Braun J, Ziring D. Proteomic analysis reveals innate immune activity in intestinal transplant dysfunction. Transplantation 2011;92:112-119.
12. Castillo RO, Wang M, Ito T, Higgins J, Esquivel CO, Krams SM, Martinez OM. Acute rejection of small intestine allografts is associated with increased expression of toll-like receptors. Transplant Proc 2010;42:2676-2678.
13. Penack O, Holler E, van den Brink MRM. Graft vs host disease regulation by microbe-associated molecules and innate immune receptors. Blood 2010;115:1865-1872
14. Zhu C, Xu H, Zhang G, Lu C, Ji M, Wu W. Myeloid differentiation factor 88-silenced bone marrow derived dendritic cells exhibit enhanced tolerogenicity in intestinal transplantation in rats. Transplant Proc 2008;40:1625-1628 (Pubitemid 351853197)
15. Murase N, Starzl TE, Tanabe M et al. Variable chimerism, graftversus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation 1995;60:158-171
16. Iwaki Y, Starzl TE, Yagihashi A, et al. Replacement of donor lymphoid tissue in small bowel transplants. Lancet 1991;337:818-819.
17. Starzl TE, Demetrius AJ, Trucco M, et al. Cell Migration and chimerism after whole-organ transplantation: The basis of graft acceptance. Hepatology 1993;17:1127-1152 (Pubitemid 23187422)
18. Abu-Elmagd KM, Costa G, Bond GJ, et al. Evolution of the immunosuppressive strategies for the intestinal and multivisceral recipients with special reference to allograft immunity and achievement of partial tolerance. Transplant International 2009;21:96-109.
19. Cai J. Intestine and multivisceral transplantation in the United States: A report of 20-year national registry data (1990-2009). Clin Transpl 2009:83-101.
20. Vianna R, Kubal C, Mangus R, Fridell J, Tector J. Intestinal and multivisceral transplantation at Indiana University: 6 years' experience with 100 cases. Clin Transpl 2009:219-28.
21. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004;4:1033-1041. (Pubitemid 38868592)
22. Archdeacon P, Chan M, Neuland C, et al. Summary of FDA antibody-mediated rejection workshop. Am J Transplant 2011;11:896-906.
23. Zeevi A, Lunz III JG, Shapiro R, et al. Emerging role of donorspecific anti-human leukocyte antigen antibody determination for clinical management after solid organ transplantation. Human Immunology 2009;70:645-650.
24. Terasaki P, Lachmann N, Cai J. Summary of the effect of de novo HLA antibodies on chronic kidney graft failure. Clin Transplant 2006:455.
25. de Serre NP, Canioni D, Lacaille F, Talbotec C, Dion D, Brousse N, Goulet O. Evaluation of c4d deposition and circulating antibody in small bowel transplantation. Am J Transplant 2008; Jun. 8:1290-1296. (Pubitemid 351763676)
26. Tsai HL, Island ER, Chang JW, et al. Association between donorspecific antibodies and acute rejection and resolution in small bowel and multivisceral transplantation. Transplantation 2011;2792:709-715.
27. Duquesnoy RJ, Awadalla Y, Lomago J, et al. Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR, DQ, DP epitopes. Transplant Immunol 2008;18:352-360. (Pubitemid 350302034)
28. Locke JE, Zachary AA, Warren DS, et al. Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am J Transplant 2009;9:2136-2139.
29. Kato T, Mizutani P, Terasaki P et al Association of emergence of HLA antibody and acute rejection in intestinal transplant recipients: A possible evidence of acute humoral sensitization. Transplant Proc 2006;38:1735-1737. (Pubitemid 44209348)
30. Gonzalez-Pinto IM, Tzakis AG, Tsai HL, et al. Association between panel reactive antibodies and acute small bowel rejection: Analysis of a series of 324 intestinal transplants. Transplant Proc 2010;42:4269-4271.
31. Jordan SC, Reinsmoen N, Lai CH, Vo A. Novel immunotherapeutic approaches to improve rates and outcomes of transplantation in sensitized renal allograft recipients. Discov Med 2012;13:235-245.
32. Abu ElMagd KM, Wu G, Costa G, et al. Preformed and de novo donor specific antibodies in visceral transplantation: Long-term outcome with special reference to the liver. Am J Transplant 2012;12:3047-3060.
33. Parizshskaya M, Riedondo C, Demetris A, et al. Chronic rejection of small bowel grafts: Pediatric and adult study of risk factors and morphologic progression. Ped Dev Path 2003;6:240-250. (Pubitemid 36676961)
34. Batal I, Zeevi A, Lunz JG 3rd, et al. Antihuman leukocyte antigenspecific antibody strength determined by complement-dependent or solid-phase assays can predict positive donor-specific crossmatches. Arch Pathol Lab Med 2010;134:1534-1540.
35. Hachem RR, Yusen RD, Meyers BF, et al. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant 2010;29:973-980.
36. Sutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB. Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant 2012;16:12-17.
37. Tyan DB. New Approaches for detecting complement-fixing antibodies. Curr Opin Transplant 2012;17:409-415.
38. Zeevi A, Lunz J. HLA antibody profiling in thoracic transplantation undergoing desensitization therapy. Curr Opin Transplant 2012;17:416-422.
39. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011;11:2405-2413.
40. Davis AE 3rd, Lu F, Mejia P. C1 inhibitor, a multi-functional serine protease inhibitor. Thromb Haemost 2010;104:886-893.
41. Everly MJ, Terasaki PI, Trivedi HL. Durability of antibody removal following proteasome inhibitor-based therapy. Transplantation 2012;93:572-577.